After getting the cellulite injection, most people get bruises that get less bad with each treatment, but in fair-skinned people, dark spots from bruising can last more than a year.
Scientific Claim
Bruising is the most common adverse event following CCH-aaes injection, with severity and duration typically decreasing across treatment sessions, and hemosiderin staining may persist for over a year in lighter-skinned patients.
Original Statement
“The most notable side effect of treatment is post-injection bruising... The duration and severity of bruising are reduced with each subsequent session... For patients with lighter skin, in particular, hemosiderin staining can be apparent for extended periods (from 6 months to beyond 1 year)...”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim describes observed adverse event patterns from clinical experience and cited studies. It does not infer causation beyond what is reported in prior trials or expert observation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1aIn EvidenceThat CCH-aaes causes significantly more bruising than placebo and that bruising severity declines across three treatment sessions.
That CCH-aaes causes significantly more bruising than placebo and that bruising severity declines across three treatment sessions.
What This Would Prove
That CCH-aaes causes significantly more bruising than placebo and that bruising severity declines across three treatment sessions.
Ideal Study Design
A double-blind RCT of 300 women receiving 3 sessions of CCH-aaes vs. saline placebo, with bruising severity quantified by digital image analysis (area, color intensity) and patient diaries at 24h, 72h, 7d, and 14d post-injection for each session.
Limitation: Cannot predict individual risk factors for prolonged staining.
Prospective Cohort StudyLevel 2bThe incidence and duration of hemosiderin staining in patients with Fitzpatrick skin types I–III after CCH-aaes treatment.
The incidence and duration of hemosiderin staining in patients with Fitzpatrick skin types I–III after CCH-aaes treatment.
What This Would Prove
The incidence and duration of hemosiderin staining in patients with Fitzpatrick skin types I–III after CCH-aaes treatment.
Ideal Study Design
A prospective cohort of 500 women with skin types I–III receiving CCH-aaes, with monthly photographic assessment for 12–24 months to document incidence, duration, and resolution of hemosiderin staining.
Limitation: Cannot determine if staining is caused by injection trauma vs. enzyme activity.
Case-Control StudyLevel 3bWhether specific patient factors (e.g., age, BMI, anticoagulant use) increase risk of prolonged bruising or hemosiderin staining.
Whether specific patient factors (e.g., age, BMI, anticoagulant use) increase risk of prolonged bruising or hemosiderin staining.
What This Would Prove
Whether specific patient factors (e.g., age, BMI, anticoagulant use) increase risk of prolonged bruising or hemosiderin staining.
Ideal Study Design
A case-control study comparing 100 patients with >6-month hemosiderin staining to 200 without, matched for skin type and treatment protocol, analyzing demographics, medications, injection depth, and technique.
Limitation: Retrospective recall bias and confounding by unmeasured variables.
Evidence from Studies
Supporting (0)
Contradicting (1)
The study talks about using the same injection for cellulite, but it doesn’t say anything about how often bruising happens, if it gets better over time, or if it leaves long-term dark spots — so we can’t say if the claim is true or false based on this study.